BACKGROUND: Burkitt's lymphoma is an aggressive B-cell lymphoma that occurs in children and adults and is largely curable with the use of intensive and toxic chemotherapy. Current treatments are less effective and have more severe side effects in adults and patients with immunodeficiency than in children. METHODS: We studied low-intensity treatment consisting of infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (EPOCH-R) in patients with untreated Burkitt's lymphoma. Two EPOCH-R regimens were tested: a standard dose-adjusted combination in human immunodeficiency virus (HIV)-negative patients (DA-EPOCH-R group) and a lower-dose short-course combination with a double dose of rituximab in HIV-positive patients (SC-EPOCH-RR group). RESULTS: A total of 30 consecutive patients were treated; 19 patients were in the DA-EPOCH-R group, and 11 in the SC-EPOCH-RR group. The overall median age of the patients was 33 years, and 40% were 40 years of age or older; 73% of the patients had intermediate-risk disease, and 10% had high-risk disease. The principal toxic events, fever and neutropenia, were observed during 22% of the DA-EPOCH-R treatment cycles and 10% of the SC-EPOCH-RR treatment cycles. The tumor lysis syndrome developed in 1 patient; no treatment-related deaths occurred. The median cumulative doses of doxorubicin-etoposide and cyclophosphamide administered in the SC-EPOCH-RR group were 47% and 57% lower, respectively, than those administered in the DA-EPOCH-R group. With median follow-up times of 86 months in the DA-EPOCH-R group and 73 months in the SC-EPOCH-RR group, the rates of freedom from progression of disease and overall survival were, respectively, 95% and 100% with DA-EPOCH-R and 100% and 90% with SC-EPOCH-RR. None of the patients died from Burkitt's lymphoma. CONCLUSIONS: In this uncontrolled prospective study, low-intensity EPOCH-R-based treatment was highly effective in adults with sporadic or immunodeficiency-associated Burkitt's lymphoma. (Funded by the National Cancer Institute; ClinicalTrials.gov numbers, NCT00001337 and NCT00006436.).
BACKGROUND:Burkitt's lymphoma is an aggressive B-cell lymphoma that occurs in children and adults and is largely curable with the use of intensive and toxic chemotherapy. Current treatments are less effective and have more severe side effects in adults and patients with immunodeficiency than in children. METHODS: We studied low-intensity treatment consisting of infused etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (EPOCH-R) in patients with untreated Burkitt's lymphoma. Two EPOCH-R regimens were tested: a standard dose-adjusted combination in human immunodeficiency virus (HIV)-negative patients (DA-EPOCH-R group) and a lower-dose short-course combination with a double dose of rituximab in HIV-positivepatients (SC-EPOCH-RR group). RESULTS: A total of 30 consecutive patients were treated; 19 patients were in the DA-EPOCH-R group, and 11 in the SC-EPOCH-RR group. The overall median age of the patients was 33 years, and 40% were 40 years of age or older; 73% of the patients had intermediate-risk disease, and 10% had high-risk disease. The principal toxic events, fever and neutropenia, were observed during 22% of the DA-EPOCH-R treatment cycles and 10% of the SC-EPOCH-RR treatment cycles. The tumor lysis syndrome developed in 1 patient; no treatment-related deaths occurred. The median cumulative doses of doxorubicin-etoposide and cyclophosphamide administered in the SC-EPOCH-RR group were 47% and 57% lower, respectively, than those administered in the DA-EPOCH-R group. With median follow-up times of 86 months in the DA-EPOCH-R group and 73 months in the SC-EPOCH-RR group, the rates of freedom from progression of disease and overall survival were, respectively, 95% and 100% with DA-EPOCH-R and 100% and 90% with SC-EPOCH-RR. None of the patients died from Burkitt's lymphoma. CONCLUSIONS: In this uncontrolled prospective study, low-intensity EPOCH-R-based treatment was highly effective in adults with sporadic or immunodeficiency-associated Burkitt's lymphoma. (Funded by the National Cancer Institute; ClinicalTrials.gov numbers, NCT00001337 and NCT00006436.).
Authors: Wyndham H Wilson; Sin-Ho Jung; Pierluigi Porcu; David Hurd; Jeffrey Johnson; S Eric Martin; Myron Czuczman; Raymond Lai; Jonathan Said; Amy Chadburn; Dan Jones; Kieron Dunleavy; George Canellos; Andrew D Zelenetz; Bruce D Cheson; Eric D Hsi Journal: Haematologica Date: 2011-12-01 Impact factor: 9.941
Authors: B Burkhardt; I Oschlies; W Klapper; M Zimmermann; W Woessmann; A Meinhardt; E Landmann; A Attarbaschi; F Niggli; M Schrappe; A Reiter Journal: Leukemia Date: 2010-10-29 Impact factor: 11.528
Authors: A Reiter; M Schrappe; M Tiemann; W D Ludwig; E Yakisan; M Zimmermann; G Mann; A Chott; W Ebell; T Klingebiel; N Graf; B Kremens; S Müller-Weihrich; H J Plüss; F Zintl; G Henze; H Riehm Journal: Blood Date: 1999-11-15 Impact factor: 22.113
Authors: J A Barnes; A S Lacasce; Y Feng; C E Toomey; D Neuberg; J S Michaelson; E P Hochberg; J S Abramson Journal: Ann Oncol Date: 2011-02-21 Impact factor: 32.976
Authors: Nina E Kontny; Gudrun Würthwein; Boos Joachim; Alan V Boddy; Miriam Krischke; Uwe Fuhr; Patrick A Thompson; Markus Jörger; Jan H M Schellens; Georg Hempel Journal: Cancer Chemother Pharmacol Date: 2013-01-13 Impact factor: 3.333
Authors: Roland Schmitz; Ryan M Young; Michele Ceribelli; Sameer Jhavar; Wenming Xiao; Meili Zhang; George Wright; Arthur L Shaffer; Daniel J Hodson; Eric Buras; Xuelu Liu; John Powell; Yandan Yang; Weihong Xu; Hong Zhao; Holger Kohlhammer; Andreas Rosenwald; Philip Kluin; Hans Konrad Müller-Hermelink; German Ott; Randy D Gascoyne; Joseph M Connors; Lisa M Rimsza; Elias Campo; Elaine S Jaffe; Jan Delabie; Erlend B Smeland; Martin D Ogwang; Steven J Reynolds; Richard I Fisher; Rita M Braziel; Raymond R Tubbs; James R Cook; Dennis D Weisenburger; Wing C Chan; Stefania Pittaluga; Wyndham Wilson; Thomas A Waldmann; Martin Rowe; Sam M Mbulaiteye; Alan B Rickinson; Louis M Staudt Journal: Nature Date: 2012-08-12 Impact factor: 49.962
Authors: Yvette L Kasamon; Robert A Brodsky; Michael J Borowitz; Richard F Ambinder; Pamela A Crilley; Steve Y Cho; Hua-ling Tsai; B Douglas Smith; Douglas E Gladstone; Hetty E Carraway; Carol Ann Huff; William H Matsui; Javier Bolaños-Meade; Richard J Jones; Lode J Swinnen Journal: Leuk Lymphoma Date: 2012-08-17
Authors: Kieron Dunleavy; Stefania Pittaluga; Lauren S Maeda; Ranjana Advani; Clara C Chen; Julie Hessler; Seth M Steinberg; Cliona Grant; George Wright; Gaurav Varma; Louis M Staudt; Elaine S Jaffe; Wyndham H Wilson Journal: N Engl J Med Date: 2013-04-11 Impact factor: 91.245
Authors: Kieron Dunleavy; Stefania Pittaluga; Margaret Shovlin; Mark Roschewski; Catherine Lai; Seth M Steinberg; Elaine S Jaffe; Wyndham H Wilson Journal: Haematologica Date: 2015-10-30 Impact factor: 9.941
Authors: Stefan K Barta; Xiaonan Xue; Dan Wang; Jeannette Y Lee; Lawrence D Kaplan; Josep-Maria Ribera; Albert Oriol; Michele Spina; Umberto Tirelli; Francois Boue; Wyndham H Wilson; Christoph Wyen; Kieron Dunleavy; Ariela Noy; Joseph A Sparano Journal: Haematologica Date: 2014-08-22 Impact factor: 9.941
Authors: Kieron Dunleavy; Michelle A Fanale; Jeremy S Abramson; Ariela Noy; Paolo Fabrizio Caimi; Stefania Pittaluga; Samir Parekh; Ann Lacasce; John W Hayslip; Deepa Jagadeesh; Sunil Nagpal; Mary Jo Lechowicz; Rakesh Gaur; Andrea Lucas; Christopher Melani; Mark Roschewski; Seth M Steinberg; Elaine S Jaffe; Brad Kahl; Jonathan W Friedberg; Richard F Little; Nancy L Bartlett; Wyndham H Wilson Journal: Lancet Haematol Date: 2018-12 Impact factor: 18.959
Authors: L Smyth; P V Browne; E Conneally; C Flynn; P Hayden; M Jeffers; D O'Brien; F Quinn; J Kelly; M Perera; G M Crotty; M Leahy; B Hennessy; F Jackson; M Ryan; E Vandenberghe Journal: Ir J Med Sci Date: 2015-04-07 Impact factor: 1.568
Authors: S K Barta; M S Samuel; X Xue; D Wang; J Y Lee; N Mounier; J-M Ribera; M Spina; U Tirelli; R Weiss; L Galicier; F Boue; R F Little; K Dunleavy; W H Wilson; C Wyen; S C Remick; L D Kaplan; L Ratner; A Noy; J A Sparano Journal: Ann Oncol Date: 2015-01-28 Impact factor: 32.976
Authors: Alyssa Bouska; Chengfeng Bi; Waseem Lone; Weiwei Zhang; Ambreen Kedwaii; Tayla Heavican; Cynthia M Lachel; Jiayu Yu; Roberto Ferro; Nanees Eldorghamy; Timothy C Greiner; Julie Vose; Dennis D Weisenburger; Randy D Gascoyne; Andreas Rosenwald; German Ott; Elias Campo; Lisa M Rimsza; Elaine S Jaffe; Rita M Braziel; Reiner Siebert; Rodney R Miles; Sandeep Dave; Anupama Reddy; Jan Delabie; Louis M Staudt; Joo Y Song; Timothy W McKeithan; Kai Fu; Michael Green; Wing C Chan; Javeed Iqbal Journal: Blood Date: 2017-08-11 Impact factor: 22.113